# A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors

Source: https://onco.cc/trials/nct06873555/  
OnCo record `nct06873555` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of DC05F01 in ovarian cancer and small-cell lung cancer, run by Heronova Pharmaceuticals, now recruiting.

## Summary

A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06873555 by Heronova Pharmaceuticals, with 60 participants planned, started 2024-09-11 and due to reach its primary completion in 2027-12. Interventions recorded: DC05F01.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06873555
- Phase: 1/2
- Setting: Phase Ib/IIa Multicenter, Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of DC05F01 in Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
- Sponsor: Heronova Pharmaceuticals
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06873555: https://clinicaltrials.gov/study/NCT06873555

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)

---
JSON: https://onco.cc/api/v1/entities/nct06873555.json